|
 U.S. stocks closed at fresh record highs on Friday on revived hopes for a U.S. - China trade deal despite mixed economic data.
|
RELATED ARTICLES | | | | |
|
 A popular exchange-traded fund that tracks the health-care sector saw its best daily return in 10 months on Friday after the Trump administration proposed new rules aimed at making health-care prices more transparent. The SPDR Health Care Select Sector ETF posted a 2.1%, marking its best day since Jan. 4, when it rose 2.98%, according to FactSet data. The Trump administration proposed a rule that would require health insurers to disclose estimated out-of-pocket costs, including negotiated rates, to patients in advance of a procedure or office visit. It also finalized a rule requiring hospitals to make transparent the prices they charge patients starting in 2021. It's possible that the stocks gained on doubts on how the rules would be enforced. "While the Trump administration's new hospital price transparency requirement is quite sweeping, the enforcement of it is quite weak - a maximum fine of $300 per day," Kaiser Family Foundation executive Larry Levitt wrote on Twitter. Shares of UnitedHealth Group Inc. , which is the largest health insurer in the U.S., and Anthem Inc. each rose roughly 5%. Shares of Tenet Healthcare Corp. and HCA Healthcare Inc. , both large hospital operators, were up at least 2%. The S&P 500 is up 24.4% year-to-date.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
|
|
An Oklahoma judge on Friday reduced the penalty Johnson & Johnson must pay over litigation stemming from the opioid epidemic.
|
|
The Dow Jones Industrial Average marks history on Friday by finishing at a round-number milestone at 28,000, but the blue-chip benchmark couldn't have scaled the thousand-point hill without a rally in Apple and shares of Home Depot.
|
|
U.S. stocks swept to fresh records as investors turned more bullish on a trade deal with China and focused on rosy consumer data. The Dow Jones Industrial Average closed about 222 points, 0.8%, higher, just above 28,000. The S&P 500 jumped 24 points, 0.8%, to close at about 3,120. The Nasdaq was about 62 points, 0.7%, higher at the close, at 8,541. Shares of J.C. Penney Co. Inc. jumped after beating earnings expectations for the recent quarter.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
|
|
Zillow Group, an American online real estate database company, which operates the largest portfolio of real estate and home-related brands on mobile and the web, focusing on all stages of the home lifecycle: renting, buying, selling and financing, has seen its stock price rise by close to 26%...
|
|
Stocks bounced on trade headlines on Friday, but the market could stall out in the week ahead if there is no real progress toward a deal.
|
|
Aurora Cannabis Inc. shares plunged to their lowest prices in more than two years Friday, after an earnings report that included disappointing numbers and plans to cut spending sent analysts racing to cut their expectations for the Canadian marijuana producer.
|
RELATED ARTICLES | | |
|
 * U.S., China getting close to trade deal-White House
adviser
|
|
Dow breaks 28,000 with big boost from one company Fox BusinessDow hits 28,000 for the first time CNNDOW 28,000! BreitbartDow tops 28,000 as US, China trade deal comes together Fox BusinessStocks- S&P 500 Soars to 6th Weekly Gain By Investing.com
|
RELATED ARTICLES | | |
|
 Crude prices and global equities markets rose on Friday, with the major U.S. indexes setting record highs, on renewed hopes that the United States and China will reach a deal to de-escalate a 16-month trade war that has crimped global growth.
|
RELATED ARTICLES | | | | |
|
Celgene Corp. is required to divest its most popular psoriasis treatment in order to be acquired by Bristol-Myers Squibb Co. , the Federal Trade Commission announced Friday. For Bristol-Myers to close on its $74 billion acquisition, Celgene will have to sell its drug Otezla for $13.4 billion to Amgen Inc. , the FTC said. "The Commission has ordered BMS to divest Otezla to preserve BMS's incentive to continue developing its own oral product for treating moderate-to-severe psoriasis," said FTC Chairman Joseph Simons in a statement. "The antitrust laws protect not only competition today, but competition in the future, especially when it comes to the development of new treatments for chronic conditions." The companies already anticipated the FTC's concerns and agreed to the deal back in August.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
|
|
More than $1bn withdrawn in past week as struggle over trade truce clips run of inflows
|
|
Private Label